Scholarlink

Purpose <p>This review aims to address the therapeutic potential of new generation of oncolytic viruses (OVs) for liver cancer with the focus on hepatocellular carcinoma (HCC).</p> Methods <p>We evaluate the therapeutic status of oncolytic virus therapy (OVT) for liver cancer, addresses the research question of how different OVs perform in treating the malignancy, and and analyze the challenges remain in their clinical treatment based on the synthesis of both preclinical and clinical studies investigating various OVs, including Herpes simplex virus (HSV), Adenovirus (AdV), Vaccinia virus (VV), Coxsackievirus (COX), and Newcastle disease virus (NDV).</p> Results <p>OVs selectively infect and lyse tumor cells, stimulating anti-tumor immunity. HSV and VV have demonstrated high efficacy and safety in studies. Genetically engineered AdV and NDV platforms, especially those expressing immune checkpoint inhibitors or cytokines, show promising anti-tumor activity. Advances in viral engineering and delivery systems have improved tumor selectivity and immune activation. Key challenges identified include host antiviral immunity, delivery efficiency, and optimal patient selection.</p> Conclusion <p>OVT represents a promising immunotherapeutic strategy for liver cancer. While significant progress has been made in both efficacy and safety through genetic modification, ongoing innovation in viral engineering, combination therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Shilin You,
  • Min Wang,
  • Tengyue Zhang,
  • Qingwen Wang,
  • Mingjun Zhang,
  • Haiting Wang,
  • Xuesi Hua,
  • Yanping Su,
  • Yongqing Li,
  • Peng Qu,
  • Ye Qiu,
  • Yinqing Li

摘要

Purpose

This review aims to address the therapeutic potential of new generation of oncolytic viruses (OVs) for liver cancer with the focus on hepatocellular carcinoma (HCC).

Methods

We evaluate the therapeutic status of oncolytic virus therapy (OVT) for liver cancer, addresses the research question of how different OVs perform in treating the malignancy, and and analyze the challenges remain in their clinical treatment based on the synthesis of both preclinical and clinical studies investigating various OVs, including Herpes simplex virus (HSV), Adenovirus (AdV), Vaccinia virus (VV), Coxsackievirus (COX), and Newcastle disease virus (NDV).

Results

OVs selectively infect and lyse tumor cells, stimulating anti-tumor immunity. HSV and VV have demonstrated high efficacy and safety in studies. Genetically engineered AdV and NDV platforms, especially those expressing immune checkpoint inhibitors or cytokines, show promising anti-tumor activity. Advances in viral engineering and delivery systems have improved tumor selectivity and immune activation. Key challenges identified include host antiviral immunity, delivery efficiency, and optimal patient selection.

Conclusion

OVT represents a promising immunotherapeutic strategy for liver cancer. While significant progress has been made in both efficacy and safety through genetic modification, ongoing innovation in viral engineering, combination therapies.